WO2003092666A1 - Agents de renforcement de tissus contenant du calcium et utilisation correspondante - Google Patents
Agents de renforcement de tissus contenant du calcium et utilisation correspondante Download PDFInfo
- Publication number
- WO2003092666A1 WO2003092666A1 PCT/JP2002/004407 JP0204407W WO03092666A1 WO 2003092666 A1 WO2003092666 A1 WO 2003092666A1 JP 0204407 W JP0204407 W JP 0204407W WO 03092666 A1 WO03092666 A1 WO 03092666A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- calcium
- containing tissue
- weight
- strengthening agent
- sold
- Prior art date
Links
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 145
- 239000011575 calcium Substances 0.000 title claims abstract description 145
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 145
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 50
- 238000005728 strengthening Methods 0.000 title claims abstract description 43
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000011957 flavonols Nutrition 0.000 claims abstract description 11
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000008758 anthocyanidins Nutrition 0.000 claims abstract description 9
- 235000011987 flavanols Nutrition 0.000 claims abstract description 9
- 150000002206 flavan-3-ols Chemical class 0.000 claims abstract description 7
- 150000002216 flavonol derivatives Chemical class 0.000 claims abstract description 7
- 229930003949 flavanone Natural products 0.000 claims abstract description 6
- 150000002208 flavanones Chemical class 0.000 claims abstract description 6
- 235000011981 flavanones Nutrition 0.000 claims abstract description 6
- 239000000126 substance Substances 0.000 claims description 60
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims description 36
- 239000003623 enhancer Substances 0.000 claims description 23
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical group C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 claims description 22
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 claims description 22
- 235000010209 hesperetin Nutrition 0.000 claims description 22
- 229960001587 hesperetin Drugs 0.000 claims description 22
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 claims description 22
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 19
- SFBODOKJTYAUCM-UHFFFAOYSA-N Ipriflavone Chemical compound C=1C(OC(C)C)=CC=C(C2=O)C=1OC=C2C1=CC=CC=C1 SFBODOKJTYAUCM-UHFFFAOYSA-N 0.000 claims description 18
- 229960005431 ipriflavone Drugs 0.000 claims description 18
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 16
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims description 14
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims description 14
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims description 14
- 229940025878 hesperidin Drugs 0.000 claims description 14
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims description 14
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims description 14
- 235000008696 isoflavones Nutrition 0.000 claims description 14
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 13
- 229930003944 flavone Natural products 0.000 claims description 13
- 235000011949 flavones Nutrition 0.000 claims description 13
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 11
- 150000002515 isoflavone derivatives Chemical class 0.000 claims description 11
- 239000011707 mineral Substances 0.000 claims description 11
- 125000001424 substituent group Chemical group 0.000 claims description 11
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 10
- 229940088594 vitamin Drugs 0.000 claims description 10
- 229930003231 vitamin Natural products 0.000 claims description 10
- 239000011782 vitamin Substances 0.000 claims description 10
- 235000013343 vitamin Nutrition 0.000 claims description 10
- 238000010521 absorption reaction Methods 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 9
- 239000002243 precursor Substances 0.000 claims description 9
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 claims description 8
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 8
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 8
- 229930014669 anthocyanidin Natural products 0.000 claims description 8
- 235000005513 chalcones Nutrition 0.000 claims description 8
- 235000005875 quercetin Nutrition 0.000 claims description 8
- 229960001285 quercetin Drugs 0.000 claims description 8
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 7
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 7
- 150000002212 flavone derivatives Chemical class 0.000 claims description 7
- NWKFECICNXDNOQ-UHFFFAOYSA-N flavylium Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=[O+]1 NWKFECICNXDNOQ-UHFFFAOYSA-N 0.000 claims description 7
- 229920001542 oligosaccharide Polymers 0.000 claims description 7
- 230000001737 promoting effect Effects 0.000 claims description 7
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 229940043430 calcium compound Drugs 0.000 claims description 6
- 150000001674 calcium compounds Chemical class 0.000 claims description 6
- 150000001720 carbohydrates Chemical group 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 239000002537 cosmetic Substances 0.000 claims description 6
- 150000002213 flavones Chemical class 0.000 claims description 6
- 229930182470 glycoside Natural products 0.000 claims description 6
- 150000002338 glycosides Chemical class 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- VEVZSMAEJFVWIL-UHFFFAOYSA-O cyanidin cation Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 VEVZSMAEJFVWIL-UHFFFAOYSA-O 0.000 claims description 5
- 235000013402 health food Nutrition 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 150000002482 oligosaccharides Chemical class 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 5
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 claims description 4
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 claims description 4
- 150000001789 chalcones Chemical class 0.000 claims description 4
- 150000007946 flavonol Chemical class 0.000 claims description 4
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 claims description 4
- 150000002681 magnesium compounds Chemical class 0.000 claims description 4
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 claims description 4
- FTVWIRXFELQLPI-CYBMUJFWSA-N (R)-naringenin Chemical compound C1=CC(O)=CC=C1[C@@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-CYBMUJFWSA-N 0.000 claims description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 3
- 239000002211 L-ascorbic acid Substances 0.000 claims description 3
- 235000000069 L-ascorbic acid Nutrition 0.000 claims description 3
- 108010001441 Phosphopeptides Proteins 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 239000005018 casein Substances 0.000 claims description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 3
- 235000021240 caseins Nutrition 0.000 claims description 3
- 235000005487 catechin Nutrition 0.000 claims description 3
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 3
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 claims description 3
- 235000007625 naringenin Nutrition 0.000 claims description 3
- 229940117954 naringenin Drugs 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 235000003687 soy isoflavones Nutrition 0.000 claims description 2
- OEIJRRGCTVHYTH-UHFFFAOYSA-N Favan-3-ol Chemical compound OC1CC2=CC=CC=C2OC1C1=CC=CC=C1 OEIJRRGCTVHYTH-UHFFFAOYSA-N 0.000 claims 2
- 235000007336 cyanidin Nutrition 0.000 claims 2
- UZMJOLAEXGRYDX-ANSQBLEFSA-N 2-[(2e,6e)-3,7-dimethyl-8-(4-methylfuran-2-yl)octa-2,6-dienyl]-5-methylcyclohexa-2,5-diene-1,4-dione Chemical compound C=1C(=O)C(C)=CC(=O)C=1C\C=C(/C)CC\C=C(/C)CC1=CC(C)=CO1 UZMJOLAEXGRYDX-ANSQBLEFSA-N 0.000 claims 1
- UZMJOLAEXGRYDX-UHFFFAOYSA-N Furanoquinone Natural products C=1C(=O)C(C)=CC(=O)C=1CC=C(C)CCC=C(C)CC1=CC(C)=CO1 UZMJOLAEXGRYDX-UHFFFAOYSA-N 0.000 claims 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 claims 1
- 150000001765 catechin Chemical class 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 72
- 229930015036 aurone Natural products 0.000 abstract description 3
- 150000001530 aurones Chemical class 0.000 abstract description 3
- 229930003939 flavanonol Natural products 0.000 abstract 1
- 150000002210 flavanonols Chemical class 0.000 abstract 1
- 229960005069 calcium Drugs 0.000 description 124
- 210000001519 tissue Anatomy 0.000 description 65
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 63
- 210000000988 bone and bone Anatomy 0.000 description 28
- 238000000151 deposition Methods 0.000 description 24
- 230000008021 deposition Effects 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 238000012360 testing method Methods 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 208000001132 Osteoporosis Diseases 0.000 description 16
- -1 vitamin D Natural products 0.000 description 16
- 239000000047 product Substances 0.000 description 15
- 239000003814 drug Substances 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 210000000963 osteoblast Anatomy 0.000 description 13
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 12
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 12
- 210000000515 tooth Anatomy 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 10
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 10
- 230000009471 action Effects 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 230000002708 enhancing effect Effects 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 235000010755 mineral Nutrition 0.000 description 7
- 150000002894 organic compounds Chemical class 0.000 description 7
- 208000004434 Calcinosis Diseases 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 6
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 6
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 6
- 239000001527 calcium lactate Substances 0.000 description 6
- 229960002401 calcium lactate Drugs 0.000 description 6
- 235000011086 calcium lactate Nutrition 0.000 description 6
- 235000015872 dietary supplement Nutrition 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 230000011164 ossification Effects 0.000 description 6
- 229960004555 rutoside Drugs 0.000 description 6
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000001110 calcium chloride Substances 0.000 description 5
- 229910001628 calcium chloride Inorganic materials 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 229930003935 flavonoid Natural products 0.000 description 5
- 150000002215 flavonoids Chemical class 0.000 description 5
- 235000017173 flavonoids Nutrition 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 229910052749 magnesium Inorganic materials 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 210000002303 tibia Anatomy 0.000 description 5
- 210000000689 upper leg Anatomy 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 208000006386 Bone Resorption Diseases 0.000 description 4
- 206010065687 Bone loss Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 4
- 230000024279 bone resorption Effects 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- 229960000905 indomethacin Drugs 0.000 description 4
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- PFPQMWRASYNLMZ-LGIMBNBCSA-N 2-(3,4-dihydroxyphenyl)-3-[(2s,3r,4r,5s,6r)-3,4-dihydroxy-5-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-5,7-dihydroxychromen-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 PFPQMWRASYNLMZ-LGIMBNBCSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930003316 Vitamin D Natural products 0.000 description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 3
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 3
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 3
- 235000005493 rutin Nutrition 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000606 toothpaste Substances 0.000 description 3
- 229940034610 toothpaste Drugs 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 239000011710 vitamin D Substances 0.000 description 3
- 235000019166 vitamin D Nutrition 0.000 description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 description 3
- 229940046008 vitamin d Drugs 0.000 description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 2
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 description 2
- 229940122361 Bisphosphonate Drugs 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000011632 Caseins Human genes 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010060891 General symptom Diseases 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229920001991 Proanthocyanidin Polymers 0.000 description 2
- 239000004373 Pullulan Substances 0.000 description 2
- 229920001218 Pullulan Polymers 0.000 description 2
- 208000010641 Tooth disease Diseases 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000003263 anabolic agent Substances 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 229940125714 antidiarrheal agent Drugs 0.000 description 2
- 239000003793 antidiarrheal agent Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 2
- 235000008714 apigenin Nutrition 0.000 description 2
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 2
- 229940117893 apigenin Drugs 0.000 description 2
- 238000002306 biochemical method Methods 0.000 description 2
- 150000004663 bisphosphonates Chemical class 0.000 description 2
- 230000008468 bone growth Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 230000003913 calcium metabolism Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229950001002 cianidanol Drugs 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 2
- 229910000393 dicalcium diphosphate Inorganic materials 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 238000007046 ethoxylation reaction Methods 0.000 description 2
- 230000006203 ethylation Effects 0.000 description 2
- 238000006200 ethylation reaction Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 150000002303 glucose derivatives Chemical group 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 235000008777 kaempferol Nutrition 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 238000006198 methoxylation reaction Methods 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 2
- 229940097496 nasal spray Drugs 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 229960003540 oxyquinoline Drugs 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- VGEREEWJJVICBM-UHFFFAOYSA-N phloretin Chemical compound C1=CC(O)=CC=C1CCC(=O)C1=C(O)C=C(O)C=C1O VGEREEWJJVICBM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 235000019423 pullulan Nutrition 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 description 1
- ZWTDXYUDJYDHJR-UHFFFAOYSA-N (E)-1-(2,4-dihydroxyphenyl)-3-(2,4-dihydroxyphenyl)-2-propen-1-one Natural products OC1=CC(O)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O ZWTDXYUDJYDHJR-UHFFFAOYSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FYELSNVLZVIGTI-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-5-ethylpyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1CC)CC(=O)N1CC2=C(CC1)NN=N2 FYELSNVLZVIGTI-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241001002469 Archips Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- OPSXJNAGCGVGOG-DKWTVANSSA-L Calcium L-aspartate Chemical compound [Ca+2].[O-]C(=O)[C@@H](N)CC([O-])=O OPSXJNAGCGVGOG-DKWTVANSSA-L 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- HBQJTBXZMPSVBP-UHFFFAOYSA-N Cyanidine Natural products OC1=CC(=C2/Oc3cc(O)cc(O)c3C=C2O)C=CC1=O HBQJTBXZMPSVBP-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000272185 Falco Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101700012268 Holin Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- YQHMWTPYORBCMF-UHFFFAOYSA-N Naringenin chalcone Natural products C1=CC(O)=CC=C1C=CC(=O)C1=C(O)C=C(O)C=C1O YQHMWTPYORBCMF-UHFFFAOYSA-N 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 241000283203 Otariidae Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000006877 Pituitary Hormones Human genes 0.000 description 1
- 108010047386 Pituitary Hormones Proteins 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 241000283080 Proboscidea <mammal> Species 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000282806 Rhinoceros Species 0.000 description 1
- OVVGHDNPYGTYIT-VHBGUFLRSA-N Robinobiose Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](C)O1 OVVGHDNPYGTYIT-VHBGUFLRSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000003732 agents acting on the eye Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229940070021 anabolic steroids Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940124605 anti-osteoporosis drug Drugs 0.000 description 1
- 229940035678 anti-parkinson drug Drugs 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 230000003208 anti-thyroid effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940043671 antithyroid preparations Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 230000002763 arrhythmic effect Effects 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229940037448 calcitonin preparations Drugs 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229960004256 calcium citrate Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 229940095672 calcium sulfate Drugs 0.000 description 1
- CNYFJCCVJNARLE-UHFFFAOYSA-L calcium;2-sulfanylacetic acid;2-sulfidoacetate Chemical compound [Ca+2].[O-]C(=O)CS.[O-]C(=O)CS CNYFJCCVJNARLE-UHFFFAOYSA-L 0.000 description 1
- JBNULYRBVMNPIS-OWJCAWTQSA-L calcium;4-[[(2r)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]butanoate;hydrate Chemical compound O.[Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCCC([O-])=O JBNULYRBVMNPIS-OWJCAWTQSA-L 0.000 description 1
- PBUBJNYXWIDFMU-UHFFFAOYSA-L calcium;butanedioate Chemical compound [Ca+2].[O-]C(=O)CCC([O-])=O PBUBJNYXWIDFMU-UHFFFAOYSA-L 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003576 central nervous system agent Substances 0.000 description 1
- 229940125693 central nervous system agent Drugs 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 150000004697 chelate complex Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 231100001010 corrosive Toxicity 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 210000002858 crystal cell Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000005115 demineralization Methods 0.000 description 1
- 230000002328 demineralizing effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000021045 dietary change Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940124568 digestive agent Drugs 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- HAMKYSLXCVKNKA-UHFFFAOYSA-N dinitro phenyl phosphate Chemical compound [O-][N+](=O)OP(=O)(O[N+]([O-])=O)OC1=CC=CC=C1 HAMKYSLXCVKNKA-UHFFFAOYSA-N 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- XMXOIHIZTOVVFB-JIZZDEOASA-L disodium;(2s)-2-aminobutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CC([O-])=O XMXOIHIZTOVVFB-JIZZDEOASA-L 0.000 description 1
- FXPVUWKFNGVHIZ-UHFFFAOYSA-L disodium;dodecyl sulfate Chemical compound [Na+].[Na+].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O FXPVUWKFNGVHIZ-UHFFFAOYSA-L 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000002637 fluid replacement therapy Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 235000015201 grapefruit juice Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 229950001260 hopantenic acid Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- GUMSHIGGVOJLBP-SLRPQMTOSA-N methyl hesperidin Chemical compound C1=C(OC)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 GUMSHIGGVOJLBP-SLRPQMTOSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940125702 ophthalmic agent Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 208000022196 parasitic skin disease Diseases 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000000810 peripheral vasodilating agent Substances 0.000 description 1
- 229960002116 peripheral vasodilator Drugs 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000003169 respiratory stimulant agent Substances 0.000 description 1
- 229940066293 respiratory stimulants Drugs 0.000 description 1
- 150000008264 rhamnoses Chemical class 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- OVVGHDNPYGTYIT-BNXXONSGSA-N rutinose Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 OVVGHDNPYGTYIT-BNXXONSGSA-N 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 229950006451 sorbitan laurate Drugs 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 239000012745 toughening agent Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/794—Ketones containing a keto group bound to a six-membered aromatic ring having unsaturation outside an aromatic ring
- C07C49/796—Ketones containing a keto group bound to a six-membered aromatic ring having unsaturation outside an aromatic ring polycyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
- C07C49/83—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups polycyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
- C07C49/835—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups having unsaturation outside an aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/83—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
- C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- An object of the present invention is to provide a non-toxic, safe and highly effective calcium-containing tissue strengthening agent, and a use thereof for foods, drinks, cosmetics, pharmaceuticals, and the like, which contains the same. Disclosure of the invention
- a substance having a basic structure represented by any one of the following general formulas 1 to 5 or a precursor thereof (hereinafter, referred to as the present specification)
- the substance may be described as a substance of the general formulas 1 to 5), which induces calcium metabolism in animals in the direction of calcium deposition, deposits calcium in calcium-containing tissues, strengthens the tissues, and thus increases bone weight. I found it to be.
- isoflavones are used together with the substances of the general formulas 1 to 5, they induce calcium metabolism in animals in the direction of calcification, deposit calcium in calcium-containing tissues, strengthen tissues, and as a result, The inventors discovered that the weight was increased, and led to the present invention.
- FIG. 1 is a graph showing the daily changes in the concentration of kenfeal, hesperetin or ipriflavone in the potent action of alkaline phosphatase activity.
- FIG. 2 is a graph showing daily changes in the concentration of kenferol or ipriflavone in the action of enhancing calcium deposition.
- X represents a single bond or a double bond; Represents an arbitrary substituent.
- the substance having the basic structure of the general formula 2 is a substance called anthocyanidins.
- the compounds shown in Table 2 are used.
- H represents a hydrogen atom
- OH represents a hydroxy group
- OCH 3 represents a methoxy group
- OG1u represents glycosylated glucose.
- R i to R i represent an arbitrary substituent.
- the substance having the basic structure of the general formula 4 is a substance called chalcone.
- the compounds shown in Table 4 are used.
- H represents a hydrogen atom and O H represents a hydroxy group.
- the substance having the basic structure of the general formula 5 is a substance called aurones.
- the compounds shown in Table 5 are used.
- H represents a hydrogen atom
- OH represents a hydroxy group
- CH 3 represents methoxy fe.
- the substances of the general formulas 1 to 5 used in the present invention that is, flavones, flavonols, flapanones, flavanolols, anthocyanidins, flavanols, chalcones and aurones, Or, the precursor is usually used in the form of aglycone or glycoside.
- the precursor is usually used in the form of aglycone or glycoside.
- even naturally occurring derivatives such as polymers thereof even if they do not have the basic structure represented by the general formulas 1 to 5, can be metabolized in vivo after ingestion.
- a substance that changes its structure to have a basic structure represented by any of general formulas 1 to 5, or a so-called derivative may be used, as long as it can enhance the power of calcium-containing tissue.
- proanthocyanidin a precursor of a kind of anthocyanidins
- proanthocyanidin polymer a persimmon tannin
- the substances of general formulas 1 to 5 or derivatives thereof are Regardless of its origin or purity, if necessary, for example, a relatively large amount of plant material is extracted with an appropriate solvent, and the resulting extract is used as it is, or is further purified to improve its purity. Can be used at elevated levels. Further, it may be obtained by artificially synthesizing, and a commercially available product can also be suitably used.
- the substances of the general formulas 1 to 5 used in the present invention are used in combination with isoflavones, which are known for the treatment or prevention of osteoporosis, the action of strengthening calcium-containing tissue is synergistically markedly enhanced.
- Isoflavones are a general term for substances having a structure represented by the general formula 6, and aglycone and / or a glycoside thereof is used as a substance to be added to the calcium-containing tissue strengthening agent of the present invention.
- the substances shown in Table 6 can be mentioned, and are suitably blended with the calcium-containing tissue strengthening agent of the present invention.
- Isoflavones are calcium deposits on calcium-containing tissues exerted by the substances of the general formulas 1 to 5 used in the present invention. As long as it can further enhance its use, regardless of its origin or purity, if necessary, for example, by extracting a relatively large amount of plant material with an appropriate solvent, The obtained extract can be used as it is, or can be further purified and used with higher purity. An example of this is soy isoflavones. Further, it may be obtained by artificially synthesizing, and further, a commercially available product can be suitably used. When a substance that is difficult to dissolve in water is used, it may be used by dissolving it with a solvent such as dimethyl sulfoxide or ethanol as long as the effect of the present invention is not impaired.
- a solvent such as dimethyl sulfoxide or ethanol
- the calcium-containing tissue referred to in the present invention is a tissue in which solid crystalline calcium, for example, calcium phosphate such as hydroxyapatite is present in a relatively large amount.
- solid crystalline calcium for example, calcium phosphate such as hydroxyapatite is present in a relatively large amount.
- Bone tissue, especially bone tissue, and tooth tissue is present in these tissues. In these tissues, the effect of the calcium-containing tissue reinforcing agent of the present invention is exhibited.
- the calcium-containing tissue strengthening agent of the present invention may further comprise, as necessary, other than the substances of general formulas 1 to 5, or the substances of general formulas 1 to 5 and isoflavones, as an active ingredient.
- Excipients such as aluminum silicate, lactose, ⁇ , ⁇ -trehalose, ⁇ , 0-tismelose, arabia gum, corn starch, crystalline cellulose, carboxymethyl Binders such as cellulose and polyvinylpyrrolidone, lubricants such as magnesium stearate and talc, disintegrants such as starch and calcium carboxymethylcellulose, and solvents such as water and ethanol. Can be.
- ⁇ , 1-trehalose is disclosed in Japanese Patent Application Laid-Open No. 2000-38043 and Japanese Patent Application Laid-Open No. 2000-198033. As mentioned above, it can be used advantageously as a drug for preventing and treating osteoporosis, and therefore can be used advantageously.
- General formula 1 contained as an active ingredient of the calcium-containing tissue enhancer of the present invention The substances (1) to (5), or the substances of the general formulas (1) to (5) and isoflavones can be formulated with the active ingredient alone or in a mixture of the active ingredient and a pharmaceutically acceptable carrier or diluent. Can be used as The amount of the active ingredient in the preparation is 0.0001% by weight or more, desirably 0.001% by weight in terms of anhydride. / 0 or more.
- the calcium-containing tissue enhancer of the present invention can be administered orally or parenterally. The dose of the calcium-containing tissue enhancer of the present invention may be sufficient to achieve the effects of the present invention, depending on the dosage form and the subject, so the dose should be limited.
- the amount of active ingredient per day It is between 0.5 and 500 mg / kg body weight, preferably between 0.5 and 200 mg / kg body weight.
- the substances represented by the general formulas 1 to 5, or the substances represented by the general formulas 1 to 5 and isoflavones used as the active ingredient of the calcium-containing tissue strengthening agent of the present invention are food additives, cosmetic raw materials, pharmaceutical raw materials, etc. Many of them have already been confirmed to be safe, and not only as a calcium-containing tissue enhancer, but also as a food, beverage, cosmetic or pharmaceutical product containing it. Can be safely administered, ingested or used.
- the calcium-containing tissue enhancer of the present invention can be applied to animals having bone and tooth tissues mainly composed of solid calcium, that is, vertebrates including humans or non-human mammals. Applicable to general.
- the calcium-containing tissue strengthening agent of the present invention is useful for treating, promoting recovery of, or preventing diseases related to bones such as osteoporosis and fractures, and weakening of alveolar bones due to caries and periodontal disease. It is effective.
- drugs such as hormonal drugs and cytokine drugs administered for the treatment of other diseases
- to prevent bone loss due to demineralization to promote the establishment of natural or artificial bone during transplantation. Is also used.
- various healthy people can be used to prevent loss of bone mass, such as bone loss due to abnormal hormone secretion in postmenopausal or postpartum women, excessive diet, and abnormal hormone secretion due to malnutrition.
- Loss of bone mass due to bedridden due to lack of exercise due to bedridden elderly people, paralysis of upper and lower limbs and long-term hospitalization, bone mass loss due to weightlessness or low weight due to space and underwater life Deterioration, excessive exercise training The effect of restoring the decrease in bone mass caused by illness or preventing bone loss in advance is exhibited. It is also effective in promoting bone formation during childhood growth and maintaining bone mass in the elderly.
- calcium in plasma is deposited on calcium-containing tissue, an effect of improving high calcium plasma can be expected depending on the method of use.
- the effects described above are not limited to humans, but include, for example, vertebrates in general, including dogs, cats, sea lions, stags, dogs, deer, rhinoceros, elephants, wild boars, etc. It can be applied to advantage.
- the calcium-containing tissue enhancer of the present invention to be incorporated into a drug can be obtained by using a conventionally known therapeutic agent for osteoporosis together with the effective amount of the calcium-containing tissue enhancer of the present invention, if necessary.
- the osteoporosis therapeutic agent include a calcitonin preparation, an estrogens preparation, a bisphosphonate preparation, a vitamin D preparation, a vitamin K preparation and the like.
- anesthetics for example, anesthetics, hypnotics, anxiolytics, antiepileptics, antipyretic analgesics and anti-inflammatory drugs, stimulants, stimulants, antiparkinson drugs, psychiatric agents, central nervous system Agent, skeletal muscle relaxant, agent for autonomic nervous system, antispasmodic, ophthalmic agent, otolaryngological agent, analgesic, cardiotonic, arrhythmic, diuretic, hypotensive, vasoconstrictor, coronary vasodilator, peripheral Vasodilators, hyperlipidemia agents, respiratory stimulants, antiseptic expectorants, bronchodilators, agents for anti-diarrheal agents, antidiarrheals, intestinals, peptic ulcers, stomach digestives, antacids, Bile drugs, pituitary hormones, salivary glands, thyroid hormones, 04407
- Antithyroid hormones anabolic steroids, corticosteroids, male sex hormones, estrogen, progestin, mixed hormones, urogenitals, anal, surgical disinfectants, wound protection Preparations, external preparations for purulent diseases, analgesics, antipruritics, astringents, anti-inflammatory agents, external preparations for parasitic skin diseases, emollients, corrosives, dental and oral preparations, vitamin preparations, inorganic preparations, Fluid replacement agent, hemostatic agent, anticoagulant agent, agent for liver disease, antidote, addictive agent, gout treatment, enzyme preparation, antidiabetic agent, antineoplastic agent, antihistamine, irritation Therapeutic agents, antibiotics, chemotherapeutic agents, biological agents, anthelmintics, antiprotozoal agents, preparation agents, agents such as X-ray contrast agents and diagnostic agents, and the content of the present invention.
- the calcium-containing tissue enhancer of the present invention contains a predetermined amount of an active ingredient in a process until its preparation is completed, for example, by a method such as mixing, kneading, dissolving, dipping, spraying, coating, spraying, or pouring. It should be done.
- the substances of the general formulas 5 to 5, or the substances of the general formulas 1 to 5 and isoflavone used in the present invention sufficiently exert their function and effect, that is, the function of depositing calcium on calcium-containing tissue.
- Calcium compounds include calcium chloride, glycete calcium phosphate, calcium dalconate, calcium lactate, calcium carbonate, calcium hydrogen phosphate, dihydrogen phosphate, calcium hopantenate, and calcium.
- Examples include calcium tothenate, calcium fusidani, calcium thioglycolate, calcium sulfate, calcium silicate, calcium acetate, calcium L-aspartate, calcium citrate, calcium lingoate, and calcium succinate. These can be used alone or in combination of two or more.
- a mineral other than calcium for example, calcium or sodium, together with the calcium compound described above. It is preferable to mix well with magnesium, manganese, phosphorus, iron, zinc, etc.
- the magnesium compound is desirably taken together with calcium to prevent high calcium plasma, etc., and the amount of the magnesium compound to be added to the calcium-containing tissue enhancer of the present invention is based on the calcium compound. It is blended in an amount of not more than equimolar, preferably in a range of 0.5 mol to 0.05 mol per mol of the calcium compound.
- the magnesium compound include magnesium oxide, magnesium chloride, magnesium carbonate, magnesium sulfate, and the like, and one or more of these can be used as appropriate.
- a substance having a mineral absorption promoting action that enhances intestinal absorption and enhances utilization in the living body is strengthened by the calcium-containing tissue of the present invention. It can also be advantageously carried out by including it in an agent.
- proteins such as casein phosphopeptides or oligopeptides, isomalt oligosaccharides, fructo. 0204407
- Oligosaccharides such as oligosaccharides, xylo-oligosaccharides, lactose, soybean oligosaccharides, a> a-trehalose, ⁇ , —trehalose, lactose, lactic acid, acetic acid, citric acid, dalconic acid, Examples include organic acids such as succinic acid, which can be advantageously used.
- vitamins in the calcium-containing tissue strengthening agent of the present invention.
- the vitamins include active vitamin D, vitamin, L-ascorbic acid, and derivatives thereof.
- the mouse pre-osteoblast cell line MC 3 ⁇ 3— ⁇ 1 cells (RC ⁇ 112)
- RC ⁇ 112 the mouse pre-osteoblast cell line MC 3 ⁇ 3— ⁇ 1 cells
- the mouse preosteoblast cell line MC3T3-E1 was 1 OmM HEPES, 10 (v / v). /.
- a 24-well plate was prepared using an ⁇ -MEM medium pH 6.8 containing the fetal calf serum (sold by Gibco BRL) and having the composition shown in Table 7 at a cell concentration of 5 ⁇ 10 4 cells / ml. were seeded (Falco emissions Becton di Tsukinso emission sold by the company) to one Anato Ri 1 m 1 5 X 1 0 4 cells until the cells adhere to the plates bottom, 3 7 ° C, 5% Culture in a carbon dioxide atmosphere Was.
- Menthol (sold by Wako Pure Chemical Industries, Ltd.), Teofirin (sold by Wako Pure Chemical Industries, Ltd.), Tocopherolone (sigma)
- ⁇ -MEM medium (10% (V / V) fetal bovine serum, 10 mM
- the containing phosphate) was added in 1 m 1. Since in the medium containing a final concentration 0 ⁇ 2% (V / V ) ethanoate Lumpur, as a negative control, containing 0 2% (V / V) ethanol alpha -. M The EM medium was used. The culture was continued for 8 days, replacing the medium with or without the fresh sample every 3 days.
- alkaline phosphatase activity was carried out according to the method of Kazy et al.
- alkaline phosphatase B-Test Co., Ltd. sold by Wako Pure Chemical Industries, Ltd.
- Sacips Op 'Oral Biology (Archivesof Oral Biology), Vol. 4, Vol. 23, pp. 23-241 (1989). That is, the medium was removed from the above mouse osteoblasts, washed three times with 1 ml of 0.25 M sucrose solution, and washed with 50 mM carbonate buffer containing ImM magnesium chloride and 50 mM sucrose.
- the solution (pH 9.8) was added in an amount of 0.45 ml and 3.4 mM p-n- sodium dinitrophenylphosphate (0.05 ml) in that order, and left at 25 ° C for 5 minutes. Thereafter, the reaction was stopped by adding 1.5 ml of 0.6 N sodium hydroxide. In the above reaction mixture, it was formed by the action of alkaline phosphatase; PT / JP02 / 04407
- the sample preparation method and cell culture method were the same as in Experiment 1, except that the number of culture days in the medium containing each test sample was limited to 5 days, and the method for measuring calcium was as in Experiment 3 and Experiment 5. Done. The concentration of ethanol contained in the medium containing each test sample was the same.
- Kenferol 5 iM, 10 iM, 20 M alone, ipriflavone 5 ⁇ , 10 j ⁇ , 2 alone, or kepriflavone with Kenferol Figure 3 shows the combination of 5 ⁇ ⁇ , 10 ⁇ , and 2 ⁇ , respectively, in which hesperetin 5 ⁇ , 10 / ⁇ , 20 / iM alone, ipriflavone 5 ⁇ , 1
- FIG. 4 shows 0 ⁇ , 20 ⁇ alone, or a mixture of heprisflatin and ipriflavone in combination with 5 ⁇ and 10 ⁇ 2 ⁇ ⁇ , respectively.
- the rat was sacrificed and the femur and tibia were removed.
- the extracted femur and tibia were dried at 100 ° C for about 6 hours, and then precision electronic balance for high-precision analysis (trade name “HA18OM / 12QM”; ) was used to measure the dry weight.
- the femur and the tibia are placed in a crucible, treated in an incinerator at 950 ° C for 6 hours, and after sufficient incineration, dissolved in a hydrochloric acid solution.
- the amount was quantified with an atomic absorption spectrophotometer.
- the amount of calcium was calculated as the amount of calcium equivalent to dry bone and compared with the control. The results are shown in Table 12.
- Table 11 Table 11
- each flavonoid needs to be in the form of aglycone, and when administered in vivo, the sugar moiety is degraded by enzymes in the intestinal tract or in vivo. It is presumed that they are decomposed and act as aglycones.
- Experiment 8 Acute toxicity test
- the test samples used were the organic compounds used in Experiment 3, namely, flavone (sold by Kanto Chemical Co., Ltd.), apigenin (sold by Funakoshi Co., Ltd.), flavonol (sold by Tokyo Chemical Industry Co., Ltd.), and quercetin (Kanto Chemical Co., Ltd.) Kyufu-guchi (sold by Funakoshi Co., Ltd.), Rutin (sold by Kanto Chemical Co., Ltd.), Hulapanone (sold by Kanto Chemical Co., Ltd.), Naringenin (sold by Aldrich), Hesperetin (sold by Funakoshi) Co., Ltd.), Hesperidin (Kanto Chemical Co., Ltd.), Chalcone (Merck Co., Ltd.), Floretin (Sigma Co., Ltd.), Catechin (Sigma Co., Ltd.), Ibri Flavone (Dight Co., Ltd.) ), Taxi Hol
- Gavage was administered at a dose of m 1 Z kg rat body weight. Thereafter, the rats were kept under constant temperature and humidity conditions, and food and water were given freely. The general symptoms and the state of life and death were observed for 14 days while measuring the body weight of each individual with the administration day being 0 day. 02 04407
- Example 1 solution After breeding for 2 weeks, none of the test samples died, there was no decrease in body weight, the appearance was good, and no remarkable general symptoms were observed. Therefore, the substances of the general formulas 1 to 5 used as active ingredients in the calcium-containing tissue strengthening agent of the present invention are judged to be extremely safe. Hereinafter, examples of the present invention will be described. Example 1 solution
- ⁇ -glycosylrutin (trade name “ a G-rutin ⁇ ⁇ ”, sold by Hayashibara Shoji Co., Ltd.) 1 part by weight, soybean isoflavone (sold by Fuji Oil Co., Ltd.) 5 parts by weight, a, ⁇ — Trehalose powder (product Name “Treha”, sold by Hayashibara Corporation) 100 parts by weight, 1 part by weight of calcium lactate, 0.5 part by weight of magnesium sulfate, uniformly mixed, dried, and powdered calcium-containing structure A toughening agent was produced.
- This stable product is easily soluble in water and contains calcium and magnesium, so it has an excellent effect of strengthening the calcium-containing tissue. It is useful as a tissue enhancer containing calcium for the treatment and prevention of osteoporosis and fractures, or as a health food such as health supplements and functional foods.
- Example 6 Lozenges
- Example 7 lozenges ⁇ -. Gris Koshiruruchin (trade name of " ⁇ G rutin ⁇ ", Hayashibara Shoji sales Co., Ltd.) 1 part by weight, and quercetin (Funakoshi Co., Ltd.
- a-Trehalose powder (trade name “Treha”, sold by Hayashibara Shoji Co., Ltd.) 52 parts by weight, corn starch 40 parts by weight, ⁇ -glycosylrutin (trade name “a G Rutin ⁇ ”, Hayashibara Shoji Co., Ltd.) 0.5 parts by weight, ⁇ -glycosyl hesperidin (trade name “aG hesperidin PA”, sold by Hayashibara Shoji Co., Ltd.) 0.5 parts by weight, L-ascorbic acid-2—darcoside (trade name “ AA2G ”, sold by Hayashibara Corporation) 0.1 parts by weight of calcium chloride and 2.5 parts by weight of crystal cell opening are mixed, and the appropriate amount of water is sprayed and kneaded while dripping according to the usual method.
- the mixture was pulverized and sized to obtain a tableting powder. After uniformly mixing 2 parts by weight of sucrose fatty acid ester as a lubricant, the mixture is compressed into tablets (approximately 300 mg / tablet) using a tableting machine equipped with a 11 mm diameter punch. I got
- This product which is easy to ingest and has good disintegration in the digestive tract, is useful as a health supplement such as a health supplement or a health functional food that maintains and enhances bone mass.
- Example 9 Linking agent
- ⁇ - Gris Koshiruruchin (trade name of " ⁇ G rutin ⁇ ", Hayashibara Shoji sales 1 part by weight, 1 part by weight of ⁇ - daricosylnalindine produced according to the method described in Example A-2 of JP-A-4-136991, 20 parts by weight of grapefruit juice, a, ⁇ — Trehalose powder (trade name “Treha”, sold by Hayashibara Corporation) 2 parts by weight, citrate 2 parts by weight, L-ascorbic acid-2-darcoside (trade name “AA 2G , Sold by Hayashibara Corporation) 1 part by weight, 5 parts by weight of isomerized sugar, 6 parts by weight of seawater, 2 parts by weight of calcium chloride, and 160 parts by weight of pure water, and filled into glass bottles 100 m1 each After that, the container was sealed and a drink was obtained.
- This product has a good flavor and has the effect of strengthening the calcium-containing tissue. Therefore, it is useful as a drink for treating and preventing osteoporosis and fractures.
- ⁇ -Dalicosyl hesperidin (trade name “G hesperidin ⁇ ⁇ ”, sold by Hayashibara Shoji Co., Ltd.) 1 part by weight, Lingo juice 50 parts by weight, isomerized sugar 5 parts by weight, L-ascorbic acid 2 parts by weight , ⁇ , a — Trehalose (trade name “Treha”, sold by Hayashibara Shoji Co., Ltd.) 3 parts by weight, 2 parts by weight of sodium L-aspartate, 35 parts by weight of water After filling each bottle with 10 O ml, the bottle was sealed and a drink was obtained.
- a calcium-containing tissue enhancer containing a substance represented by any one of the general formulas 1 to 5 or a precursor thereof exhibits strong calcium deposition activity in preosteoblasts or osteoblasts. Since it is synergistically significantly enhanced by its addition, it has a bone growth and bone formation promoting effect and a bone mass increasing effect, and is contained in health foods such as health supplements and health functional foods. Not only can it be ingested, but it can be easily consumed without any discomfort even when it comes to everyday food and drink.
- the calcium tissue enhancer of the present invention is particularly useful for preventing the weakening of bones and teeth in elderly people and for treating and preventing osteoporosis. In addition, it is highly effective for young people to prevent delays in bone growth and bone formation caused by dietary changes.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Physical Education & Sports Medicine (AREA)
- Mycology (AREA)
- Botany (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020047017557A KR100946822B1 (ko) | 2002-05-01 | 2002-05-02 | 칼슘 함유 조직 강화제 및 그 용도 |
US10/513,119 US20050215493A1 (en) | 2002-05-01 | 2002-05-02 | Calcium-containing tissue strengthening agents and use thereof |
EP02807341.9A EP1514540B1 (en) | 2002-05-01 | 2002-05-02 | Calcium-containing tissue strengthening agents and use thereof |
US12/210,587 US8778882B2 (en) | 2002-05-01 | 2008-09-15 | Agent for strengthening calcium containing tissue and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002130154A JP4390428B2 (ja) | 2001-05-01 | 2002-05-01 | 含カルシウム組織強化剤 |
JP2002-130154 | 2002-05-01 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10513119 A-371-Of-International | 2002-05-02 | ||
US12/210,587 Division US8778882B2 (en) | 2002-05-01 | 2008-09-15 | Agent for strengthening calcium containing tissue and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003092666A1 true WO2003092666A1 (fr) | 2003-11-13 |
Family
ID=29397322
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/004407 WO2003092666A1 (fr) | 2002-05-01 | 2002-05-02 | Agents de renforcement de tissus contenant du calcium et utilisation correspondante |
Country Status (5)
Country | Link |
---|---|
US (2) | US20050215493A1 (ja) |
EP (1) | EP1514540B1 (ja) |
KR (1) | KR100946822B1 (ja) |
TW (1) | TWI331032B (ja) |
WO (1) | WO2003092666A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1643863A2 (en) * | 2003-07-10 | 2006-04-12 | Carl A. Forest | Foods, beverages, condiments, spices and salad dressings with specialized supplements |
JP2011513390A (ja) * | 2008-03-05 | 2011-04-28 | カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ | 骨系疾患の予防・治療用の、ウルムスワリチアーナから分離した新規なフラボノール化合物、生物活性抽出物/フラクション、及びその化合物 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG162773A1 (en) * | 2005-03-11 | 2010-07-29 | Florey Howard Inst | Flavonoid compounds and uses thereof |
EP2368442B1 (en) | 2005-07-27 | 2014-12-17 | Symrise AG | Use of hesperetin for enhancing the sweet taste |
US20070092454A1 (en) * | 2005-10-24 | 2007-04-26 | Colgate-Palmolive Company | Oral composition containing morin |
US20070116836A1 (en) * | 2005-11-23 | 2007-05-24 | The Coca-Cola Company | High-Potency Sweetener Composition for Treatment and/or Prevention of Osteoporosis and Compositions Sweetened Therewith |
US9101160B2 (en) | 2005-11-23 | 2015-08-11 | The Coca-Cola Company | Condiments with high-potency sweetener |
US20070269541A1 (en) * | 2006-05-19 | 2007-11-22 | Peter Rohdewald | Method and compositions for relieving menopausal and perimenopausal symptoms |
US20080003300A1 (en) * | 2006-06-30 | 2008-01-03 | Gaffar Maria C | Compostions containing Mg/Zn/F-CaP plus inhibitors of pro-inflammatory Cytokines (a combination of a Free-B-Ring flavonoids and a flavan) for osteoporosis prevention, therapy and treatment of bone diseases |
GB0614353D0 (en) | 2006-07-20 | 2006-08-30 | Oraldent Ltd | Oral compositions, their preparation and use |
JP5296697B2 (ja) * | 2006-10-24 | 2013-09-25 | クレンピン,ローリー | 抗再吸収及び骨構築食事サプリメント及び使用方法 |
US8017168B2 (en) | 2006-11-02 | 2011-09-13 | The Coca-Cola Company | High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith |
US7871648B2 (en) * | 2007-04-02 | 2011-01-18 | Alfredo Avila | Herbal formulation for the treatment of bone fractures and osseous defects |
CA2712647C (en) | 2008-01-28 | 2016-08-30 | Beauty Pearl Group Limited | Formulas comprising calcium, magnesium, zinc, and vitamin d3 for the prevention and amelioration of osteoporosis |
CA2800121C (en) * | 2010-06-03 | 2016-12-20 | Stokely-Van Camp, Inc. | Electrolyte blends providing reduced salty taste |
JP2013542924A (ja) | 2010-09-17 | 2013-11-28 | ストークリー−ヴァン キャンプ インコーポレイテッド | 血中乳酸濃度を減少させる方法 |
CN103211836A (zh) * | 2013-04-11 | 2013-07-24 | 天津天狮生物发展有限公司 | 一种治疗骨质疏松的组合物 |
US11517603B2 (en) | 2017-09-21 | 2022-12-06 | Hokuriku University | Bone remodeling accelerator |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63156720A (ja) * | 1986-12-20 | 1988-06-29 | Kissei Pharmaceut Co Ltd | 骨粗鬆症治療剤 |
JPS63156721A (ja) * | 1986-12-22 | 1988-06-29 | Kissei Pharmaceut Co Ltd | 骨粗鬆症治療剤 |
JPS63156722A (ja) * | 1986-12-22 | 1988-06-29 | Kissei Pharmaceut Co Ltd | 骨粗鬆症治療剤 |
JPS63156723A (ja) * | 1986-12-22 | 1988-06-29 | Kissei Pharmaceut Co Ltd | 骨粗鬆症治療剤 |
JPS63201124A (ja) * | 1987-02-14 | 1988-08-19 | Kissei Pharmaceut Co Ltd | 骨粗鬆症治療剤 |
JPS63201123A (ja) * | 1987-02-14 | 1988-08-19 | Kissei Pharmaceut Co Ltd | 骨粗鬆症治療剤 |
US5525618A (en) * | 1993-04-05 | 1996-06-11 | Hoechst Japan Limited | Method of treating bone disease with pyridine, carboxamide and carboxylic derivatives |
JPH119221A (ja) * | 1997-06-26 | 1999-01-19 | Honen Corp | 抗骨粗鬆症組成物 |
EP0906761A2 (en) * | 1997-10-02 | 1999-04-07 | Archer-Daniels-Midland Company | Method of preparing and using phytochemicals |
JP2000080035A (ja) * | 1998-09-02 | 2000-03-21 | National Institute Of Fruit Tree Science | マトリックスメタロプロテアーゼ産生阻害剤 |
JP2001072582A (ja) * | 1999-09-07 | 2001-03-21 | Sunstar Inc | 機能性経口組成物 |
JP2001114675A (ja) * | 1999-10-12 | 2001-04-24 | Fancl Corp | ビタミン組成物 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3060227B2 (ja) * | 1989-06-03 | 2000-07-10 | 株式会社林原生物化学研究所 | α―グリコシル ヘスペリジンとその製造方法並びに用途 |
US5478579A (en) * | 1991-02-06 | 1995-12-26 | Biodyn Medical Research, Inc. | Method for treatment of osteoporosis |
US6297273B1 (en) * | 1996-04-02 | 2001-10-02 | Mars, Inc. | Use of cocoa solids having high cocoa polyphenol content in tabletting compositions and capsule filling compositions |
CA2284290A1 (en) * | 1997-03-20 | 1998-09-24 | Samuel Russell Vester | Nutritional supplement for cardiovascular health |
EP1656942A3 (en) * | 1997-08-08 | 2008-02-27 | Otsuka Pharmaceutical Co., Ltd. | Isoflavone-containing composition |
US6117429A (en) * | 1997-08-11 | 2000-09-12 | Weider Nutrition International, Inc | Compositions and treatments for reducing potential unwanted side effects associated with long-term administration of androgenic testosterone precursors |
WO1999065337A1 (en) * | 1998-06-19 | 1999-12-23 | Beth Israel Deaconess Medical Center | Dietary supplement for post-menopausal women |
ID28460A (id) * | 1998-07-08 | 2001-05-24 | Lipogenics Inc | Komposisi dan metoda untuk perlakuan dan pencegahan penyakit tulang dengan menggunakan tocotrienol |
AU4550100A (en) * | 1999-05-05 | 2000-11-21 | Herzog, Leslie J. | Food product |
AU6801200A (en) * | 1999-08-27 | 2001-03-26 | Amway Corporation | Dietary food supplement containing natural cyclooxygenase inhibitors |
EP1127572A3 (en) | 2000-02-25 | 2003-05-02 | Basf Aktiengesellschaft | Use of flavones for treating cycloxygenase-2 mediated diseases |
BR0111210A (pt) * | 2000-06-02 | 2003-12-16 | Merck Patent Gmbh | Composição para o tratamento e/ou prevenção de osteoporose e/ou doenças de juntas inflamatórias |
-
2002
- 2002-05-02 WO PCT/JP2002/004407 patent/WO2003092666A1/ja active Application Filing
- 2002-05-02 US US10/513,119 patent/US20050215493A1/en not_active Abandoned
- 2002-05-02 KR KR1020047017557A patent/KR100946822B1/ko active IP Right Grant
- 2002-05-02 EP EP02807341.9A patent/EP1514540B1/en not_active Expired - Fee Related
- 2002-05-02 TW TW091109304A patent/TWI331032B/zh not_active IP Right Cessation
-
2008
- 2008-09-15 US US12/210,587 patent/US8778882B2/en not_active Expired - Fee Related
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63156720A (ja) * | 1986-12-20 | 1988-06-29 | Kissei Pharmaceut Co Ltd | 骨粗鬆症治療剤 |
JPS63156721A (ja) * | 1986-12-22 | 1988-06-29 | Kissei Pharmaceut Co Ltd | 骨粗鬆症治療剤 |
JPS63156722A (ja) * | 1986-12-22 | 1988-06-29 | Kissei Pharmaceut Co Ltd | 骨粗鬆症治療剤 |
JPS63156723A (ja) * | 1986-12-22 | 1988-06-29 | Kissei Pharmaceut Co Ltd | 骨粗鬆症治療剤 |
JPS63201124A (ja) * | 1987-02-14 | 1988-08-19 | Kissei Pharmaceut Co Ltd | 骨粗鬆症治療剤 |
JPS63201123A (ja) * | 1987-02-14 | 1988-08-19 | Kissei Pharmaceut Co Ltd | 骨粗鬆症治療剤 |
US5525618A (en) * | 1993-04-05 | 1996-06-11 | Hoechst Japan Limited | Method of treating bone disease with pyridine, carboxamide and carboxylic derivatives |
JPH119221A (ja) * | 1997-06-26 | 1999-01-19 | Honen Corp | 抗骨粗鬆症組成物 |
EP0906761A2 (en) * | 1997-10-02 | 1999-04-07 | Archer-Daniels-Midland Company | Method of preparing and using phytochemicals |
JP2000080035A (ja) * | 1998-09-02 | 2000-03-21 | National Institute Of Fruit Tree Science | マトリックスメタロプロテアーゼ産生阻害剤 |
JP2001072582A (ja) * | 1999-09-07 | 2001-03-21 | Sunstar Inc | 機能性経口組成物 |
JP2001114675A (ja) * | 1999-10-12 | 2001-04-24 | Fancl Corp | ビタミン組成物 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1643863A2 (en) * | 2003-07-10 | 2006-04-12 | Carl A. Forest | Foods, beverages, condiments, spices and salad dressings with specialized supplements |
JP2011513390A (ja) * | 2008-03-05 | 2011-04-28 | カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ | 骨系疾患の予防・治療用の、ウルムスワリチアーナから分離した新規なフラボノール化合物、生物活性抽出物/フラクション、及びその化合物 |
JP2015038134A (ja) * | 2008-03-05 | 2015-02-26 | カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチCouncil Of Scientific & Industrial Research | 骨系疾患の予防・治療用の、ウルムスワリチアーナから分離した新規なフラボノール化合物、生物活性抽出物/フラクション、及びその化合物 |
Also Published As
Publication number | Publication date |
---|---|
EP1514540A4 (en) | 2006-03-08 |
KR100946822B1 (ko) | 2010-03-09 |
US8778882B2 (en) | 2014-07-15 |
US20050215493A1 (en) | 2005-09-29 |
TWI331032B (ja) | 2010-10-01 |
EP1514540B1 (en) | 2014-08-27 |
US20090075908A1 (en) | 2009-03-19 |
KR20040101576A (ko) | 2004-12-02 |
EP1514540A1 (en) | 2005-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8778882B2 (en) | Agent for strengthening calcium containing tissue and use thereof | |
US20060264497A1 (en) | Diindolylmethane-based compositions and methods of use thereof for promoting oral mucosal and bone health | |
JP4390428B2 (ja) | 含カルシウム組織強化剤 | |
JPH11302142A (ja) | 歯周病の予防又は治療用の食品組成物、口腔用組成物及び医薬組成物 | |
KR20000019716A (ko) | 바이오플라보노이드 화합물을 포함하는 혈당 강하용 조성물 | |
JP3648587B2 (ja) | 歯周病予防又は歯周病進行予防食品組成物 | |
US20230302075A1 (en) | Preparations containing berry extracts for use in the prophylaxis and/or treatment of viral infections caused by coronaviridae | |
CA2605651A1 (en) | Compositions and methods for treating or preventing overweight or obesity with zinc-charged protein fragments | |
WO2005046702A1 (ja) | 歯槽骨の吸収及び歯根膜喪失を抑制する方法及びそれに用いる内服組成物 | |
JP2008088113A (ja) | 美白組成物 | |
JP3749978B2 (ja) | 抗骨粗鬆症作用を発揮する骨形成増進組成物 | |
JP2002029953A (ja) | 歯周病の予防または治療用の食品組成物、口腔用組成物 | |
KR101879398B1 (ko) | 망고스틴 추출물 및 프로폴리스 추출물을 포함하는 골형성 촉진용 조성물 및 이의 제조방법 | |
JP2010132575A (ja) | 美白剤およびその利用 | |
WO2019098811A2 (ko) | Chp(시클로-히스프로)를 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물 | |
EP1677627A1 (en) | Dietetic preparation with hyaluronate for treatment of osteoporosis | |
KR102219572B1 (ko) | Lpar2 저해제를 포함하는 상아질-치수질환 또는 치주질환 예방 또는 치료용 약학적 조성물 | |
JP3441411B2 (ja) | コレステロール低減化ペプチド | |
KR20100113417A (ko) | 조골세포 증식 및 분화 촉진, 골석회화 촉진 및 파골세포의 분화 억제 효과를 갖는 황금 추출물 | |
JP4584453B2 (ja) | バイオフラボノールの混合物を含む組成物 | |
WO2007026897A1 (ja) | しみ又はそばかす予防又は治療用経口組成物及び食品 | |
JP3523248B2 (ja) | コレステロール低減化ペプチド | |
JP2002121146A (ja) | 歯周病予防用製剤 | |
WO2010086736A2 (en) | Novel use of the combination of resveratrol with cysteine and derivatives thereof | |
KR20220120521A (ko) | 퀼라야 추출물을 함유하는 소취용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10513119 Country of ref document: US Ref document number: 1020047017557 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002807341 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020047017557 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2002807341 Country of ref document: EP |